Balsalazide in treating colonic diseases. - Wikidata - awgldk - TriplyDB

Balsalazide in treating colonic diseases.

Balsalazide in treating colonic diseases.

http://www.wikidata.org/entity/Q37587217

about

A Case of Balsalazide-Induced Limited Form of Granulomatosis with Polyangiitis with Bronchiolitis Obliterans Organizing Pneumonia-like Variant in Ulcerative Colitis

P2860

Q36434307-D3C4EC43-B235-432F-A5CD-1D50D9483570

P2860

Balsalazide in treating colonic diseases.

http://www.wikidata.org/entity/Q37587217

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Balsalazide in treating colonic diseases.

@en

Balsalazide in treating colonic diseases.

@nl

type

label

Balsalazide in treating colonic diseases.

@en

Balsalazide in treating colonic diseases.

@nl

prefLabel

Balsalazide in treating colonic diseases.

@en

Balsalazide in treating colonic diseases.

@nl

P1433

Q37587217-A3977EA8-7C18-41D9-8967-89336377D86B

P1476

Q37587217-553C781F-4A03-451A-A3DF-FFD39590EC3B

P2093

Q37587217-78FA1374-479F-48F4-83FF-B1534A4251BD

P2860

Q37587217-03CF82B9-F0FC-4DE6-9040-C01281DE8D39

Q37587217-0ACC57A8-5E96-4EEB-B91A-DCEEBB5AE3DF

Q37587217-135E6A08-D2DA-4BDF-B670-CB05C90E6BDB

Q37587217-1603561E-5DC1-430C-8309-5F643EEEC378

Q37587217-1CD7E68D-2FA2-49FD-9AB7-491FFF8896D0

Q37587217-27D0C00B-9C85-4C83-BEB4-355DF9461B63

Q37587217-2AA13F96-F607-4B2C-88D5-0BB10EDCD0D3

Q37587217-2EC18CE3-8A4A-4861-BDF1-BF2DEC65528C

Q37587217-32E811A3-B0EA-42AB-BBDA-5A29B01F3116

Q37587217-372B3F5C-D2FE-4E8A-B56E-9A806F96820E

P304

Q37587217-5A06AAEA-B969-4A93-A91B-4E5741307F6D

P31

Q37587217-9DF03F97-0B3C-4331-BF73-13F26E053DB6

P356

Q37587217-46B61B40-8E8F-4F5A-9FF0-CC081401DD30

P407

Q37587217-3CDA513D-FF81-4BDA-8771-9152912E8A38

P433

Q37587217-E2561AF5-B941-4AEB-A8C8-F1A78F678669

P478

Q37587217-4665121D-8B14-44FC-B192-6F8D5165732B

P577

Q37587217-C0663BFA-11A7-4573-B09F-FDC8C311A7DA

P5875

Q37587217-C246C2A4-4D17-49D3-94AB-CED9561A4B8F

P698

Q37587217-274377D9-D25F-4BFC-849E-4D44B92721CB

P356

17425250903228842

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Balsalazide in treating colonic diseases.

@en

P2093

Antonio Tursi

http://www.w3.org/2001/XMLSchema#string

P2860

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

Inflammatory bowel disease

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate

Review article: balsalazide therapy in ulcerative colitis.

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations.

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

PPARgamma as a new therapeutic target in inflammatory bowel diseases

Medical therapy for ulcerative colitis 2004.

How important is onset of action in ulcerative colitis therapy?

P304

1555-1563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425250903228842

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26768859

http://www.w3.org/2001/XMLSchema#string

P698

19708827

http://www.w3.org/2001/XMLSchema#string